Lactobacillus Reuteri DSM17648 – an alternative in the first-line of helicobacter pylori eradication

The present study included 70 patients diagnosed with Helicobacter pylori infection by the rapid urease test, randomized into two therapeutic regimens: Lactobacillus reuteri DSMZ17648, liquorice and calcium carbonate and classical proton pump inhibitor – amoxicillin – clarithromycin scheme. The eradication efficiency was 54.3% in the Lactobacillus reuteri group vs 77.1% in the antibiotic group (p = 0.042) but with a significantly lower rate of side effects (2.9% vs 17.1%, p = 0.037). Finding new drugs to eradicate Helicobacter pylori with increased efficacy, cost effectiveness ratio and no side effects remains a challenge.

Keywords: Helicobacter pylori, eradication, antibiotic resistance, Lactobacillus reuteri

Shopping Cart
Scroll to Top

New Name. New Website.

We have changed our name from Nouveau Health to Nouveau Healthcare and we've moved from nouveauhealth.co.uk to nhinnovations.com.

We hope you enjoy using your new platform.